In more detail

Background

Under Regulation 23 of the Regulations, the HSA is required to consider whether a patent is in force in respect of a therapeutic product that is sought to be registered.

Therapeutic product applicants must, at the time of their application, furnish to the HSA a patent declaration stating whether any patent is in force in respect of the relevant product and whether the applicant is the proprietor of the patent. Where the applicant is not the proprietor of the patent, the applicant must declare that:

• the patentee has consented to or has acquiesced in the grant of the registration;
• the patent is invalid; or
• the patent will not be infringed by acts relating to the therapeutic product.

The patent declaration requirement is intended to minimize potential patent disputes before HSA's grant of registration, and does so by notifying patent proprietors of registration of products subject to a patent during the patent term without their consent or acquiescence.

Any person who makes a false patent declaration shall be guilty of an offense and be liable on conviction to a fine not exceeding SGD 20,000 and/or imprisonment for up to 12 months. If an applicant fails to declare relevant patents, patentees may also bring an action for a declaration that the applicant infringed a patent or omitted to disclose material information when obtaining registration of a generic therapeutic product. Such a declaration can be used to seek cancellation of the product's registration and marketing approval.

Key proposed changes

Having received feedback that the existing regulations lack clarity and create uncertainty as to the requirements for patent declarations, the HSA's proposed regulations specify that the following patent declarations must be furnished to the HSA during registration of therapeutic products:

• a patent containing a claim for an active ingredient of that therapeutic product;
• a patent containing a claim for a formulation or composition of that therapeutic product;
• a patent containing a claim for the use of an active ingredient in the manufacture of that therapeutic product for a specific therapeutic, preventive, palliative or diagnostic use.

Patents that do not fall within the abovementioned categories are not subject to the declaration requirement in Regulation 23 of the Regulations.

HSA intends for these legislative changes to provide clarity to organizations on the type of patents to be considered in patent declarations in order to better facilitate the therapeutic products registration system.

Public consultation

The HSA welcomes feedback on the proposed regulation for patent declarations. Feedback may be provided until 31 March 2024.

* * * * *

© 2024 Baker & McKenzie.Wong & Leow. All rights reserved. Baker & McKenzie.Wong & Leow is incorporated with limited liability and is a member firm of Baker & McKenzie International, a global law firm with member law firms around the world. In accordance with the common terminology used in professional service organizations, reference to a "principal" means a person who is a partner, or equivalent, in such a law firm. Similarly, reference to an "office" means an office of any such law firm. This may qualify as "Attorney Advertising" requiring notice in some jurisdictions. Prior results do not guarantee a similar outcome.